ClinicalTrials.gg
RecruitingNCT05964101GALAXY-1Updated Nov 9, 2026

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

A Phase 2 interventional study of Nivolumab Injection [Opdivo] in Neoplasms, Carcinoma, Squamous and Antineoplastic Agents, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionCarcinoma, Squamous CellRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Squamous Cell
Why
  1. The study's listed conditions name Carcinoma, Squamous Cell, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Phase 2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Nov 9, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing nivolumab in Carcinoma, Squamous Cell — 3 open to participants now, 4 under way, 1 of them phase 3. Nivolumab · Carcinoma, Squamous Cell.

Planned enrollment
7th of 11
25 · median 35
Started
2023
the only one that year
Phase 2
7 of 11
2 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
The First Affiliated Hospital of Guangzhou Medical University

Among the 11 studies testing nivolumab in Carcinoma, Squamous Cell, this one is the 7th largest by planned enrollment, is the only one that started in 2023, is one of 7 in phase 2, and was the 8th registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

3 of the 11 studies testing nivolumab in Carcinoma, Squamous Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nivolumab in Carcinoma, Squamous Cell, or all of them as a file.
02

Study summary

This is a single-arm, open, II phase study to evaluate the safety and efficacy of Nivolumab + carboplatin + paclitaxel in 25 newly diagnosed patients with primary tracheal squamous cell carcinoma.

Read the detailed description

Primary tracheal tumors are rare, comprising 0.01-0.4% of all cancer cases. Most airway tumors present with non-specific symptoms, such as shortness of breath and a sore throat, which may not be attributable to the tumors themselves, leading to diagnostic delay. With limited treatment options, surgical resection is considered the cornerstone therapy. Neoadjuvant therapy is recommended as standard treatment for the early stages (stage IB/II) and locally advanced stages (stage IIIA) of non-small cell lung cancer (NSCLC). Whether neoadjuvant therapy affects subsequent pathological or surgical outcomes of primary tracheal tumors remains unclear. This study aimed to characterize the outcomes of neoadjuvant therapy for the treatment of primary tracheal squamous cell carcinoma.

03

Conditions studied

  • Neoplasms
  • Carcinoma, Squamous
  • Antineoplastic Agents

Browse trials for

Keywords

  • tracheal tumor
  • neoadjuvant immunochemotherapy
  • surgery
04

In context

Carcinoma, Squamous Cell Reclassified

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

This study's planned enrollment of 25 is below the median of 45 across 478 interventional studies indexed under Carcinoma, Squamous Cell.

Browse Carcinoma, Squamous Cell studies →

Lead sponsor

The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.

Compared within Carcinoma, Squamous Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Bronchoscopic confirmed as tracheal squamous cell carcinoma by pathological examination
  2. PET-CT confirmed no ;
  3. physical status score 0-1;
  4. Bronchoscopy, and chest CT is evaluated as early or locally advanced tracheal malignant tumor, and radical surgery is expected to be feasible or after therapy.
  5. Age ≥ 18 years;
  6. Have one at least;
  7. Good function of other major organs (liver, kidney, blood system, etc.):- ((ANC) ≥ 1.5 × 109), (≥ 100 × 109), (≥ 90g/L). Note: patients shall not receive blood transfusion or growth factor support within 14 days before blood collection during the screening period;-International standardized ratio () or prothrombin time (PT) ≤ 1.5 × normal upper limit ();-activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;- serum total ≤ 1.5 × ULN (Gilbert syndrome patients with total bilirubin must be \< 3×ULN). Fertile female patients with aspartate and (AST and ALT) ≤ 2.5 × ULN, or liver metastasis with AST and ALT ≤ 5 × ULN
  8. Fertile female patients must voluntarily take effective measures more than 120 days after chemotherapy or the last administration of Nivolumab, whichever is later, and the urine or serum pregnancy test results less than 7 days before entering the group were negative. Unsterilized male patients must voluntarily take effective contraceptive measures ≥ 120 days after chemotherapy or the last administration of Nivolumab, whichever is the latter.
  9. Sign ;

Exclusion criteria

Exclusion Criteria:

  1. Any Chinese herbal medicine used to control cancer was used within 14 days before the first administration of the study drug;
  2. Patients with other malignant tumors in the five years before the start of this trial.
  3. Complicated with unstable systemic diseases, including active infections, uncontrolled hypertension, unstable angina pectoris, congestive heart failure [higher than II (New York College of Cardiology)], severe arrhythmias, liver, kidney or metabolic diseases;
  4. Active, known or suspected diseases, or autoimmune paraneoplastic syndrome requiring systemic treatment;
  5. A history of active bleeding or embolism within 6 months, or received thrombolysis or anticoagulation therapy, or the researchers believe that there is an obvious tendency of gastrointestinal bleeding (such as esophageal varices have the risk of bleeding, local active ulcer lesions, etc.);
  6. Had is suffering from nephrotic syndrome
  7. Allergic to experimental drugs;
  8. Complicated with infection or active hepatitis.
  9. Vaccination within 4 weeks before the start of this trial;
  10. Those who had undergone other major operations or severe injuries within the previous 2 months;
  11. Clinically uncontrolled pleural effusion or ascites requiring pleural or abdominal puncture drainage within 2 weeks before admission;
  12. Pregnant or lactating women;
  13. Those with neurological diseases or mental disorders.
  14. Participated in another therapeutic clinical study at the same time;
  15. Other researchers did not consider it appropriate to enroll in the group.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Nivolumab

    Neoadjuvant treatment stage: Nivolumab 360mg, Carboplatin AUC5+ paclitaxel 100 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with primary tracheal squamous cell carcinoma received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.

    Drug: Nivolumab Injection [Opdivo]

Interventions

  • DrugNivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel

    Also known as: carboplatin, paclitaxel

07

What researchers measure

Primary outcomes

  1. Safety: frequency of severe adverse events

    The frequency of severe adverse events from the participants enrolling to 30 days after the last drug administration or 30 days after surgery or new anti-cancer therapy, which comes first.

    Time frame: up to 5 months

  2. R0 rate

    There were no visible tumors in the surgical margin, and the tumor cells in the surgical margin within 1mm were negative under the microscope

    Time frame: up to 4 months

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from the enrollment of the subject to the first determination of disease progression or death of any cause according to RECISTv1.1, whichever occurs first.

    Time frame: up to 24 months

  2. Overall survival (OS)

    It is defined as the time from enrollment to death of participant due to any cause. In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date. In the event of a patient with the survival status unknown, the date when the patient is last known to be alive will be used for interpolation (censoring).

    Time frame: up to 60 months

  3. Disease control rate (DCR)

    The proportion of patients whose best overall remission (BOR) is CR, PR or disease stable (SD) according to RECISTv1.1 evaluation

    Time frame: up to 60 months

  4. Duration of remission (DOR)

    According to the time from the first recording of objective remission to relapse or death from any cause determined by RECISTv1.1, whichever occurs first.

    Time frame: up to 60 months

  5. Major pathologic response (MPR)

    MPR is defined as the proportion of participants who have achieved major pathologic response (on routine hematoxylin and eosin staining, tumors with no more than 10% viable tumor cells) in all participants who have completed the neoadjuvant therapy before surgery

    Time frame: up to 4 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2027, 47 months after the start.

Of 87 non-industry phase 2 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 82. This study's planned 47 months is below that.

Counting every sponsor, half of 98 studies reached it within 61 months; a quarter within 37 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Oct 2023 → Aug 2023, primary completion Aug 2025 → Aug 2027 and completion May 2026 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2023
First posted
Jul 27, 2023
StartActual
Aug 15, 2023was Oct 2023
Primary completionEst.
Aug 1, 2027was Aug 2025
CompletionEst.
May 31, 2028was May 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2023→Aug 15, 2023
Nov 9, 2026
Primary completion
Aug 1, 2025→Aug 1, 2027
Nov 9, 2026
Study completion
May 31, 2026→May 31, 2028
Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Major pathologic response (MPR)Now R0 rateTime frame: up to 4 months
Nov 9, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore R0 rateNow Major pathologic response (MPR)Time frame: up to 4 months
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Oct 1, 2023→Aug 15, 2023
    Primary completion Aug 1, 2025→Aug 1, 2027
    Study completion May 31, 2026→May 31, 2028
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Major pathologic response (MPR)Now R0 rateTime frame: up to 4 months
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore R0 rateNow Major pathologic response (MPR)Time frame: up to 4 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05964101
Responsible party
Shuben Li (Professor, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
Jul 27, 2023
Start date
Aug 15, 2023
Primary completion
Aug 1, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Shuben Li, PhD
Contact
13500030280@163.com
+8613500030280
Shuben Li, PhD
study chair · The First Affiliated Hospital of Guangzhou Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion